Body Composition (BC), beyond Body Mass Index (BMI) and sarcopenia, has a major prognostic impact on patients with refractory advanced Colorectal C...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter C. Van Bogaert
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors C. Van Bogaert1, C. Vandeputte1, L. Ameye1, M. Paesmans1, T. Guiot1, A. Deleporte1, N. Charette1, A. Hendlisz1, M. Jarosz2, S. Gugała-Mirosz3
  • 1Institut Jules Bordet, Brussels, Belgium, /
  • 2National Food and Nutrition Institute, Warsaw, Poland, /
  • 3The National Food and Nutrition Institute, Warsaw, Poland, /

Abstract

While obesity is a risk factor for the development of colorectal cancer (CRC), it has been associated with prolonged overall survival (OS) after cancer diagnosis. However, BMI alone is poorly correlated with muscle mass, which is also considered as a major prognostic factor in cancer patients. By contrast, the prognostic value of the fat mass composition is poorly studied. This study was designed to confirm, in patients with chemorefractory aCRC candidates for regorafenib therapy, the results of a previous study (SoMore-ClinicalTrials NCT01290926) which suggested a high prognostic value for BC, including Muscle Index (MI), Fat Mass Indexes (FMI) and densities.